Evidence map›Paper›PMID 38785918›Full record

ReviewBiomolecules2024

Navigating the Evolving Landscape of Primary Hyperoxaluria: Traditional Management Defied by the Rise of Novel Molecular Drugs.

Yueqi Huang, Wei Zhu, Jia Zhou, Qiulin Huang, Guohua Zeng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Synthesis andInternational journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yueqi HuangThe First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China.
Wei ZhuDepartment of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, China.
Jia ZhouThe First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China.
Qiulin HuangThe First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China.
Guohua ZengThe First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China.

Funding

Hunan Province Foundation of High-level Health Talent 225 ProgramNational Key Research and Development Program 2020YFC2002700National Natural Science Foundation of China 82070721National Natural Science Foundation of China 82270798Science and Technology Plan Project of Guangzhou 202102010150
6 · The paper itself

Abstract

Primary hyperoxalurias (PHs) are inherited metabolic disorders marked by enzymatic cascade disruption, leading to excessive oxalate production that is subsequently excreted in the urine. Calcium oxalate deposition in the renal tubules and interstitium triggers renal injury, precipitating systemic oxalate build-up and subsequent secondary organ impairment. Recent explorations of novel therapeutic strategies have challenged and necessitated the reassessment of established management frameworks. The execution of diverse clinical trials across various medication classes has provided new insights and knowledge. With the evolution of PH treatments reaching a new milestone, prompt and accurate diagnosis is increasingly critical. Developing early, effective management and treatment plans is essential to improve the long-term quality of life for PH patients.

Indexed as

Hyperoxaluria, PrimaryCalcium OxalateHumansOxalatesQuality of LifeCalcium OxalateOxalatesAGXTgeneticsGRHPRHOGA1oxalateprimary hyperoxaluriaRNA interference

Identifiers

PMID38785918
PMCPMC11117870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.